Cara Therapeutics Inc
(NAS:CARA)
$
0.304
0.0159 (5.52%)
Market Cap: 16.68 Mil
Enterprise Value: -21.94 Mil
PE Ratio: 0
PB Ratio: 23.38
GF Score: 33/100 Cara Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 13, 2021 / 03:00PM GMT
Release Date Price:
$12.88
(-1.90%)
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research
Good day, everybody, and thanks for joining us at the Bank of America Annual Healthcare Conference. My name is Jason Gerberry, I'm one of the biopharma analysts at BofA, and I'm pleased to be introducing our next company presenter, Cara Therapeutics and CEO, Derek Chalmers. So Derek, first off, thanks for joining us at the conference this year.
Derek T. Chalmers
Cara Therapeutics, Inc. - Co-Founder, President, CEO & Director
Good morning, Jason. Thanks for the invitation.
Jason Matthew Gerberry;Derek T. Chalmers<
BofA Securities, Research Division - MD in US Equity Research
Great. So look, Cara is one of the companies at the forefront of developing anti-itch (technical difficulty) one of the company's best medications and I know you've got some prepared remarks and some slides that you want to reference out of the gates. So maybe I'll hand the mic over to you, and then we can jump into Q&A after that.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot